Abemaciclib, palbociclib, and ribociclib are three oral CDK4/6 inhibitors that successfully secured FDA approval for advanced breast cancer (BC) patients with hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2-) tumor status[9]. Here, CDK4 is linked to breast carcinoma.